Progenics Pharmaceuticals Inc. (PGNX)

[vinmantoo]

It's not clear what the barrier to entry is, or is going to be, on generic radiopharmaceuticals. Compound pharmacies licensed for nuclear medicine have handled this work in the past and are fully capable.

The point is, it takes time and money to do make a generic, and you still have to do some kind of FDA testing. The cancers are slow growing and rare so the patients available for testing will be few. The cancers are slow growing so testing won't be quick. As I said, the market is small, and a competitor won't come in and split the market, but likely get much less than half. I doubt there will be a rush or demand for a generic. I am not going to worry about a possible competitor emerging in 10 years or so before Azedra has been sold to a single patient. I am much more interested/concerned about how quickly sales get ramp up.